1 – 50 of 111
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Clinical and genetic analyses of a Swedish patient series diagnosed with ataxia
(
- Contribution to journal › Article
-
Mark
EEG Frequency Correlates with α2-Receptor Density in Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Economic Burden of Parkinson’s Disease : A Multinational, Real-World, Cost-of-Illness Study
2024) In Drugs - Real World Outcomes(
- Contribution to journal › Article
- 2023
-
Mark
Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease
2023) In European Journal of Neurology(
- Contribution to journal › Article
-
Mark
A systematic practice review : Providing palliative care for people with Parkinson’s disease and their caregivers
2023) In Palliative Medicine(
- Contribution to journal › Scientific review
-
Mark
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden : An observational cohort study
2023) In Journal of Neurology, Neurosurgery and Psychiatry(
- Contribution to journal › Article
-
Mark
A Paradigm Shift in the Management of Patients with Parkinson's Disease
(
- Contribution to journal › Scientific review
-
Mark
Meaning in Life in Late-Stage Parkinson’s Disease : Results from the Care of Late-Stage Parkinsonism Study (CLaSP) in Six European Countries
2023) In Journal of Religion and Health(
- Contribution to journal › Article
-
Mark
Application of single wrist-wearable accelerometry for objective motor diary assessment in fluctuating Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
The Impact of COVID-19 on Parkinson's Disease : A Case-Controlled Registry and Questionnaire Study on Clinical Markers and Patients' Perceptions
(
- Contribution to journal › Article
-
Mark
Patient perspective in hereditary ataxia
(
- Contribution to journal › Published meeting abstract
-
Mark
Time to workforce exit after a Parkinson's disease diagnosis
(
- Contribution to journal › Article
-
Mark
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration
(
- Contribution to journal › Article
-
Mark
Levodopa Dose Equivalency in Parkinson's Disease : Updated Systematic Review and Proposals
(
- Contribution to journal › Article
-
Mark
Agreement between Parkinson Disease Home Diary and Observer Assessments before and after Structured Patient Training
(
- Contribution to journal › Article
-
Mark
Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum : Revelations from the MANAGE-PD validation cohort
(
- Contribution to journal › Article
-
Mark
Clinical Impression of Severity Index for Parkinson's Disease and Its Association to Health-Related Quality of Life
(
- Contribution to journal › Article
-
Mark
The Relationship between PDQ-8 and Costs in Parkinson's Disease—A Swedish Register-Based Study
(
- Contribution to journal › Article
-
Mark
Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
(
- Contribution to journal › Scientific review
-
Mark
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease : clinical and therapeutic considerations
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Safinamide in the treatment pathway of Parkinson’s Disease : a European Delphi Consensus
(
- Contribution to journal › Article
-
Mark
Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study
(
- Contribution to journal › Article
-
Mark
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease : Real-World Evidence From G7 Countries
(
- Contribution to journal › Article
-
Mark
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease
(
- Contribution to journal › Article
-
Mark
Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries
(
- Contribution to journal › Article
-
Mark
Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain : rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
(
- Contribution to journal › Article
-
Mark
Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort
(
- Contribution to journal › Article
-
Mark
Gait and balance among people with de novo vs. mild to moderate Parkinson’s disease
2022) 6th International Conference on Neurology and Brain Disorders (Virtual)(
- Contribution to conference › Abstract
-
Mark
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
(
- Contribution to journal › Scientific review
-
Mark
High risk of developing dementia in Parkinson’s disease : a Swedish registry-based study
(
- Contribution to journal › Article
-
Mark
Objective Observer vs. Patient Motor State Assessments Using the PD Home Diary in Advanced Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
(
- Contribution to journal › Article
-
Mark
Patients’ Perspective in Hereditary Ataxia
2022) In Cerebellum(
- Contribution to journal › Article
-
Mark
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease : A Systematic Review and Bayesian Network Meta-analysis
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Seizures and Epilepsy in Dementia : Diagnosis and Management
2021) p.251-290(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
The Non-Motor Symptoms Scale in Parkinson’s disease : Validation and use
(
- Contribution to journal › Scientific review
-
Mark
Perspectives on Care for Late-Stage Parkinson's Disease
(
- Contribution to journal › Scientific review
-
Mark
Longitudinal prediction of falls and near falls frequencies in Parkinson's disease:a prospective cohort study
(
- Contribution to journal › Article
-
Mark
Effects of safinamide on pain in patients with fluctuating Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Parkinson's Disease with Device, Diary, or in Disguise. Dyskinesia reduction, motor state evaluation, and workforce participation among persons with Parkinson's disease.
2021) In Lund University Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Digital health technology for non-motor symptoms in people with Parkinson's disease : Futile or future?
(
- Contribution to journal › Scientific review
-
Mark
Validation and clinical value of the MANAGE-PD tool : A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications
(
- Contribution to journal › Article
-
Mark
Clinical Usefulness of Retropulsion Tests in Persons with Mild to Moderate Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease : A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Parkinson's Disease and Post–COVID-19 Syndrome : The Parkinson's Long-COVID Spectrum
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Parkinson’s disease in Sweden—resource use and costs by severity
(
- Contribution to journal › Article
-
Mark
Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson’s Disease : A Swedish Register-Based Study in 1823 Observations
(
- Contribution to journal › Article